Cardiac Amyloidosis Screening and Management in Patients with Heart Failure: An International African Survey
Introduction
Cardiac amyloidosis (CA) is increasingly recognized as an important yet frequently underdiagnosed cause of heart failure. In many African settings, limited awareness, diagnostic resources, and referral pathways contribute to delayed or missed diagnoses.
This survey, coordinated by Amyloidosis Africa in collaboration with African cardiac societies and clinical partners, aims to assess current levels of awareness, diagnostic capacity, and management practices related to cardiac amyloidosis among healthcare professionals across the continent. The study forms part of the Amyloidosis Africa Initiative on cardiac amyloidosis screening and implementation research in Africa, which seeks to support earlier recognition, strengthen diagnostic pathways, and promote collaborative research in cardiovascular diseases across African health systems.
Findings from this survey will help inform future regional initiatives and will contribute to the design of the PREDICT-AMY Africa Study, which will evaluate the feasibility of AI-assisted ECG screening for cardiac amyloidosis in resource-limited settings.
Purpose
The aim of this survey is to collect information on:
- Healthcare professionals’ experience in diagnosing and managing cardiac amyloidosis.
- Availability and use of diagnostic modalities such as echocardiography, cardiac MRI, bone scintigraphy (e.g., 99mTc-PYP), and genetic testing.
- Access to disease-modifying therapies (DMTs) and local referral pathways.
Duration
The survey will take approximately 10–12 minutes to complete and will remain open until 15 August 2026. Participation is voluntary, and you may withdraw at any time before submission.
PREDICT-AMY Kenya
Study Duration
18 months
Confidentiality
Your responses will remain strictly anonymous. No identifying personal data will be collected. All data will be stored securely and analyzed only in aggregate form by the Amyloidosis Africa Data Management and Biostatistics Team in accordance with Good Clinical Data Management Practices (GCDMP). The findings will be used solely for scientific and educational purposes and may be published.

